Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-1 sampled and quarantined community after a COVID-19 2 outbreak - the CoNAN study 3 4 5 Sebastian Weis^{1,2,3} André Scherag⁴, Michael Baier⁵, Michael Kiehntopf⁶, Thomas Kamradt⁷, Steffi Kolanos¹, Juliane Ankert¹, Stefan Glöckner⁵, Oliwia Makarewicz¹, Stefan Hagel¹, Christina Bahrs^{1,8}, Aurelia Kimmig¹, Hans Proquitté⁹, Joel Guerra^{1,2}, Bettina Löffler⁵, Mathias 6 7 W. Pletz ¹ and the CoNAN study group. 8 9 10 ¹ Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, 11 Germany ² Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany 12 ³ Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany 13 ⁴ Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, 14 15 Germany ⁵ Institute of Medical Microbiology, Jena University Hospital, Jena, Germany 16 17 ⁶ Institute of Clinical Chemistry and Laboratory Diagnostics and Integrated Biobank 18 Jena (IBBJ), Jena University Hospital, Jena, Germany ⁷ Institute of Immunology, Jena University Hospital, Jena, Germany 19 20 ⁸ Department of Medicine I. Division of Infectious Diseases and Tropical Medicine. Medical University of Vienna, Vienna, Austria 21 22 ⁹ Children's Hospital, Jena University Hospital, Jena, Germany 23 24 25 26 Number of words: 3.294 27 Number of tables: 2 28 Number of figures: 4 29 Number of references: 30 30 31 **Study Group** 32 Technische Universität Ilmenau, Ilmenau, Germany: Thomas Hotz 33 Local Cooperation partners: Petra Enders, Renate Koch, Steffen Mai, Matthias Ullrich 34 35 Thuringian state office for consumer protection, Bad Langensalza, Germany: Dagmar Rimek. 36 37 Institute of Clinical Chemistry and Laboratory Diagnostics and Integrated Biobank Jena 38 (IBBJ), Jena, Germany: Cora Richert, Cornelius Eibner, Bettina Meinung, Kay Stötzer, Julia 39 Köhler. 40 41 Children's Hospital, JUH, Jena, Germany: Hans Cipowicz, Christine Pinkwart 42 43 Department of Anesthesiology and Intensive Care Medicine, JUH, Jena, Germany: Michael 44 Bauer, Petra Dickmann, Annika Licht, Juliane Scholz, Wibke Wetzker. 45

1 Institute for Infectious Disease and Infection Control, JUH, Jena, Germany: Anita Hartung, 2 Daniel Weiss, Lara Thieme, Gabi Hanf, Clara Schnizer, Jasmin Müller, Jennifer Kosenkow, 3 Franziska Röstel 4 5 Institute of Immunology, JUH, Jena, Germany: Nico Andreas, Raphaela Marquardt 6 7 Institute of Medical Microbiology, JUH, Jena, Germany: Stefanie Deinhardt-Emmer, Sebastian 8 Kuhn 9 10 11 12 **Corresponding Author:** 13 14 Mathias W. Pletz, MD 15 Sebastian Weis, MD 16 Institute for Infectious Diseases and Infection Control 17 Am Klinikum 1 18 Jena University Hospital 19 07747 Jena, Germany 20 21 Tel: +49.3641.9-324794 22 Fax: +49.3641.9-324652 23 Mail: Mathias.Pletz@med.uni-jena.de; Sebastian.Weis@med.uni-jena.de 24 25 26 Keywords: SARS-CoV-2, antibody response, immunity, quarantine

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Weis S. et al. CoNAN

ABSTRACT Background: Due to the substantial proportion of asymptomatic and mild courses many SARS-CoV-2 infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed at determining and characterizing the rate of SARS-CoV-2 infections and the resulting immunity in a defined population. Methods: CoNAN is a population-based cohort study in the previously guarantined community Neustadt-am-Rennsteig, Germany six weeks after a SARS-CoV-2 outbreak with 49 cases identified by PCR screening of all 883 inhabitants. The primary objective of the study was to assess SARS-CoV-2 antibody seroconversion rate using six different IgG detecting immunoassays. Secondary objectives of the study were: i.) to determine the rate of seroconversion in children; ii.) to determine potential risk factors for symptomatic vs. asymptomatic Covid19 courses; iii.) to investigate the rate of virus persistence. Findings: We enrolled 626 participants (71% of the community population). All actual SARS-CoV-2 PCR tests were negative; while a total of 8.4% (52 of 620 tested) had antibodies against SARS-CoV-2 in at least two independent tests. Twenty of the antibody positive participants had previously a positive SARS-CoV-2 PCR. On the contrary, of those 38 participants with SARS-CoV-2 infection, only 20 (52-6%) were antibody positive. Interpretation: Several antibody tests conducted six weeks after an outbreak of SARS-CoV-2 did not detect all previously PCR-positive tested individuals. Cautious evaluation of antibody testing strategies to assess immunity against the infection is warranted. Funding: CoNAN was funded by the Thuringian Ministry for Economic Affairs, Science and Digital Society (TMWWDG).

SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) is an emerging pandemic pathogen transmitted by smear, droplet and fomite infection ^{1,2}. There are neither vaccines

Weis S. et al. CoNAN

INTRODUCTION

1

2

3 4

5

6

7

8

9

10

11

12

13

14

15 16

17

18

19

20 21

22

23

24

25

26

2728

29

30

31

32

33 34

35

36

37

38

39

40

41

42

43

44

45 46

47

48

49

50

51

nor specific therapies currently available. The rate of asymptomatic infections is unclear and most of the symptomatic cases take a mild course. However, approximately 15% of the patients and especially older individuals develop a severe disease, i.e. progressive pneumonia and multi-organ failure that is associated with increased mortality 1,3. Non-medical measures to prevent the spread of SARS-CoV-2 are currently based on the interruption of infection chains through "social distancing", public masking, school closure and reduction of public life ("lockdown"). These have proven to be effective 4, yet, they are also associated with substantial social and economic impact. Therefore, a "lockdown"- approach will only be accepted by the societies as long as the advantages, i.e. protection of those most vulnerable to severe courses of the disease surpass its associated disadvantages 5. However, it needs to be taken into account that an early "exit" out of the lockdown is likely to be associated with increasing infection rates that could result in a "second wave of infection". Hence, the consequences of such a "lockdown exit", will depend on the extent of the population that remains vulnerable to severe disease courses. It has been argued, that the risk to acquire the infection is minimized if a large percentage of the population has been infected with SARS-CoV-2 and has, at least partially, developed immunity against it ⁶, which is referred to as herd immunity 5. Several population-based cohort studies have therefore tried to determine the proportion of infected persons by measuring the sero-prevalence of anti-SARS-CoV2 antibodies. Most of these studies have used only one or two different antibody assays and omitting infants, whom to include is a challenge in such studies. The largest bias

of sero-prevalence studies is probably caused by the antibody assays used. Methodology

papers have shown that there are tremendous differences between the currently available

SARS-CoV-2 antibody assays with a test specificity ranging from 84-3-100% in pre-COVID-19

specimens and inter-test agreements ranged from 75-7-94-8% 7,8. To address some of the constraints, we aimed at determining and characterizing the rate of SARS-CoV-2 infections and the resulting immune responses in a defined population. We chose a population-based approach including infants and used six different IgG antibody assays in parallel. The study was conducted in Neustadt-am-Rennsteig, a village in the Ilm district in central Thuringia, Germany with 883 inhabitants in which a SARS-CoV-2 outbreak had occurred. On March 22nd, 11 confirmed Covid-19 cases had been diagnosed in the district of which 6 (55%) were Neustadt residents with further 69 residents classified as contact persons. As a consequence, local public health authorities declared a 14-day quarantine on the entire village in which residents were also not allowed to leave the village. With support of the local family physician, an outbreak containment team of the public health department conducted a mandatory mass screening using nasopharyngeal swabs starting on April 1st in which 865 SARC-CoV-2 PCR tests were performed resulting in the diagnosis of overall 49 SARS-CoV-2 infections. With the initiated containment measures, the outbreak was controlled and the transmission to neighboring villages was prevented. There were three SARS-CoV-2 associated deaths. Due to the isolated location of the village and the clear and controlled outbreak, Neustadt-am-Rennsteig is well suited to study the sero-conversion and immunity of SARS-CoV-2 infections.

METHODS

Study design and enrollment

The CoNAN study (Covid-19 outbreak in Neustadt-am-Rennsteig) is an ongoing exploratory population-based cohort study. We here report the baseline characteristics of the participants at the time of the outbreak/quarantine initiation and at study initiation. Follow-up assessments are planned after 6 and 12 months relative to baseline assessment. All households in the

community of Neustadt-am-Rennsteig were informed by mail prior to study initiation about the aims of study. Study participation is voluntary and can be withdrawn at any time, refusal to participate has no consequences. Participants were enrolled from May 12th to 16th 2020 at a central study site that was set-up in the villages' town hall and additional until May 22nd by home visits. After informed consent, questionnaires, blood samples and pharyngeal washes were directly taken at the study site. Pediatricians were part of the study team to adequately involve under-aged participants and to ensure their appropriate sampling as well. At the study site, plasma was directly centrifuged at 4°C/2,000 *g* for 10 minutes and stored at 8°C. Pharyngeal washes were obtained after a short mouth wash with non-sparkling water under direct supervision of a study team member to ensure appropriate quality. Samples were transported twice a day to the Jena University Hospital allowing a timely further processing at the participating research institutes. Participants who could not come to the study site were enrolled by the local primary care physician at their respective homes until the 22nd of May.

14 Ethics review, data protection and data management

- 15 The study was conducted according to the current version of the Declaration of Helsinki and
- 16 has been approved by the institutional ethics committees of the Jena University Hospital and
- 17 the respective data protection commissioner (approval number 2020-1776) and the ethics
- committee of the Thuringian chamber of physicians. All data were collected with unique
- 19 pseudonyms on paper case report forms. These identifiers were later used to merge the
- questionnaire information with the laboratory information in an electronic study database.
- 21 Study registrations was applied at the German Clinical Trials Register: DRKS00022416.

Inclusion Criteria

1

2

3

4

5

6

7

8

9

10

11

12

13

22

26 27

- 23 All inhabitants of the community of Neustadt-am-Rennsteig regardless of age, gender or
- 24 infections status were eligible for participation. Informed consent was provided by the
- 25 participants or the parents/legal representatives.

Exclusion Criteria

- 28 Individuals that do not reside in Neustadt-am-Rennsteig or that live in the adjacent community
- of Kahlert were not eligible for inclusion.

30 Objectives and outcomes

- 31 The primary objective was to determine the SARS-CoV-2 antibody status (sero-conversion
- 32 rate) of the population of Neustadt-am-Rennsteig with a defined distance to the end of the
- quarantine period. SARS-CoV-2 antibody status was defined as "positive" if participants had a
- positive test result in ≥ 2 of the six antibody tests (details below); otherwise participants were
- 35 classified as "negative". The secondary objectives of the study were: *i.*) to determine the rate
- 36 of seroconversion in children; ii.) to determine potential risk factors for symptomatic vs.
- 37 asymptomatic Covid19 courses; iii.) to investigate the rate of virus persistence (as part of
- 38 future follow-up assessments).

39 Questionnaire

- 40 Participants completed a pseudonymized questionnaire directly at the study site. Clusters
- 41 were reconstructed using the family name, address and information of household members
- 42 as provided in the questionnaire. After re-assessing the original paper case report forms,
- 43 obvious errors were corrected, and duplicated entries were deleted. Plausibility checks of
- 44 demographic data were performed. Symptoms were noted if reported. Strength and duration
- 45 of symptoms was not weighted in the analysis of this manuscript. Self-reported information on
- 46 a positive SARS-CoV-2 PCR test at the time point of the outbreak/quarantine initiation was
- 47 double-checked with the information by the health department of the Ilm-district if the
- participants gave their permission on the consent form.

SARS-CoV-2 RT-PCR

Detection of SARS-CoV-2 in pharyngeal wash samples was performed by RT-PCR amplification of SARS-CoV-2 E-gene and S-gene fragments. 200 µL of the pharyngeal washes were first processed for RNA extraction in the InnuPure C16 using the innuPREP virus DNA/RNA kit (both: Analytik Jena, Jena, Germany). Subsequently, the detection of Eand S-gene of SARS-CoV-2 was performed by using the RealStar SARS-CoV-2 RT-PCR kit 1.0 (altona Diagnostics, Hamburg, Germany) on a Rotor-Gene Q real-time PCR cycler (Qiagen, Hilden, Germany). The amplification protocol consisted of a reverse transcription step at 55°C for 20 minutes, a denaturation step at 95°C for 2 minutes and subsequent 45 cycles at 95°C/55°C/72°C for 15/45/15 seconds, respectively. A positive result was defined as amplification of E- and S-gene in a sample with each cycle threshold value (ct) less than 37. Results from apparently inhibited samples with insufficient internal controls (ct > 37) were verified by using a second RT-PCR test. For these samples, RNA was once again extracted from the original pharyngeal wash specimens via QIASymphony using the QIAsymphony DSP Virus/Pathogen MiniKit (Qiagen) according to manufacturer's instructions. Subsequently, the RT-PCR step was performed on a LightCycler 480 II (F. Hoffmann-La Roche AG, Basel, Switzerland) using the LightMix Modular Sarbecovirus E-gene kit (TIB MOLBIOL, Berlin, Germany). All steps were performed according to the manufacturer's instructions.

SARS-CoV-2 antibody testing

Detection of SARS-CoV-2 IgG antibodies was performed with six different quantification methods, of which two were enzyme-linked immunosorbent assays (ELISA) and four were chemiluminescence-based immunoassays (CLIA/CMIA). In addition, a lateral flow assay (combined IgG/IgM), one IgA (ELISA) and two IgM immunoassays (ELISA and CLIA) were performed that in this setting cannot be directly compared to the IgG immunoassays and will therefore not be reported in this manuscript. All tests were carried out according to manufacturers' instructions. For detailed information on assay characteristics and instruments used see *Supplementary Table 1*. Sensitivities and specificities are shown as provided by the manufacturer. The following assays were used; EDI Novel Coronavirus SARS-CoV-2 IgG ELISA kit (Epitope Diagnostics Inc., San Diego, USA), SARS-CoV-2 IgG ELISA kit (Euroimmun, Lübeck, Germany), SARS-CoV-2 S1/S2 IgG CLIA kit (DiaSorin, Saluggia, Italy), 2019-nCoV IgG kit (Snibe Co., Ltd., Shenzhen, China), SARS-CoV-2 IgG CMIA kit (Abbott, Chicago, USA) and Elecsys Anti-SARS-CoV-2 kit (Roche, Basel Switzerland).

Statistical Analysis

Sample size considerations

The samples size of the CoNAN-cohort is fixed by the number of inhabitants (n=883) of the community of Neustadt-am-Rennsteig. We aimed at including the population as completely as possible. In addition, we consulted the WHO population-based age-stratified sero-epidemiological investigation protocol for SARS-CoV-2 infection 9 . On the basis of this recommendation, we estimated that a study with 600 samples (*i.e.* an inclusion rate of about 70%) should be sufficient to estimate a (true) seroconversion rate <10%/<20% with an expected margin of error of \pm 3%/ \pm 4% (defined by the expected width in percent points of the 95% confidence interval for the seroconversion point estimate using "Confidence interval for proportion using normal approximation (n large)" of nQuery 4-0).

Data analysis

All statistical analyses were performed in the analysis population sometime stratified by age (adults/children and adolescents) and sero-status from the serological tests. Descriptive analyses included the calculation of mean with standard deviation (SD) and medians with minimum and maximum values for continuous variables, and absolute counts (n, with percentages) for categorical variables. Owing to the great data completeness, we performed

no data imputations. As inferential statistics, we applied logistic regression models exploring the associations between the participant-reported symptoms, the SARS-CoV-2 PCR-results of the initial mass testing and the binary serostatus outcome. To adjust estimates for cluster effects between participants living in the same household (derived from their address information) we applied generalized estimation equations (GEE) with exchangeable correlation structure and logistic link function. In addition, we adjusted some of the models for sex and age (linear). Results of logistic GEE models are presented as odds ratio (OR) point and interval estimates. Results are presented such that OR>1 indicate increasing odds for a sero-positive finding with increasing exposures. All confidence intervals (CI) were calculated with 95% coverage. CIs are Wald CIs that are not adjusted for multiple comparisons. Similarly, all reported p-values are unadjusted and two-sided. Due to the explorative nature of the study, we avoided "statistical significance testing". We used the R Language for Statistical Computing (version 4.0.2; R Core Team 2019: R: A Language and Environment for Statistical Computing, Vienna, Austria) for all analyses.

RESULTS

Participant characteristics

A total of 626 of the 883 inhabitants (71%) participated in the study. Pharyngeal washes were obtained from 617 (98-6 %) participants at the time of the inclusion. All PCR tests were negative. Plasma samples were obtained from a total of 620 (99%) participants who define the analyzed sample cohort. Of those 620 analyzed participants, 58 (9%) were adolescents and children (<18 years of age at inclusion) and 36 (6%) of these were 12 years of age or younger. Figure 1 shows a flow-chart of the CoNAN study. Characteristics of the participants are given in Table 1 and Supplementary Figure 1. In four participants the results of the initial PCR-testing during the outbreak could not be revealed. None of these had anti-SARS-CoV2 antibodies.

All six serological tests were performed in 600 (96%) participants. In the remaining 20 individuals (4%), five tests were used for final analysis because, either there was limited material available or the results were inconclusive in one out of the six tests. A comparative performance of the tests is shown in *Figure 2*. In 610 participants, pharyngeal washes and serological test were performed. Upset Plot showing the comparison of test performance between the six serological IgG tests used to evaluate the antibody response in the CoNAN study

Antibody tests

We found that 52/620 (8-4%) participants had anti-SARS-CoV-2 IgG antibodies of which 20 had been test positive by PCR during the prior sampling at the SARS-CoV-2 outbreak (*Figure 3A; Table 1,2*). Among the antibody-positive participants, there was one child. Therefore, approximately six weeks after proven SARS-CoV-2 infection, antibodies were only detectable in 38-5% participants. Twelve participants with PCR-proven SARS-CoV-2 infection had no symptoms consistent with a respiratory infection or sickness during the last two months, while 180 PCR-negative participants and 168 antibody-negative participants reported respiratory symptoms during the same period, potentially reflecting common respiratory infections in springtime (*Figure 3B*). Thirteen of the 52 seropositive participants (25%) did not report any symptoms of the SARS-CoV-2 infection (*Figure 3C*). Interestingly, two of them; a 55-year old male and a 73-year old male had been tested positive for SARS-CoV-2 infection. In 26 participants, only one out of six serologic tests returned positive. These patients were judged to reflect uncertain cases and assessed as sero-negative for the comparison shown in *Figure 3*. Three of these had previously been tested positive for SARS-CoV-2 infection.

Antibody tests and self-reported symptoms

Figures 3B,C display a summary of the self-reported symptoms that basically summarizes any of the 14 questions related to symptoms into one variable, Figure 4 is a more detailed depiction at individual symptoms in all participants (Figure 4A) or stratified by the initial SARS-CoV-2 PCR-results (Figure 4B,C). Loss of smell and taste were the best predictors of later seropositivity irrespective of stratification with odds ratios point estimates ≥ 10. Interestingly, in individuals that knew they were initially PCR negative, perceived muscle and joint pain, sweats and chills, shortness of breath or fatigue turned out to be predictors of later seropositivity as well. All three investigated variables were strongly associated with OR of 17·37 (95-%Cl 8·10-37·24) for PCR vs. antibody status, an OR of 6·33 (95%-Cl 2·84-14·11) for PCR vs. any reported symptom and an OR of 8·71 (95%-Cl 4·02-18·89) for antibody status vs. any reported symptom, respectively.

DISCUSSION

We performed a population-based cohort study enrolling 71% of the population of a central-German village six weeks after a SARS-CoV-2 outbreak with subsequent community quarantining. Our data shows strikingly lower number of seropositive participants than we had expected based on the initial mass screening and the estimates of asymptomatic infections previously reported ¹⁰ ¹¹ ¹². Only 8-4% of the tested population were seropositive for anti SARS-CoV-2 antibodies in which 6-2% (38/610) had proven SARS-CoV-2 infection, indicating a low rate of asymptomatic cases.

It is currently unknown why in some patients with previously PCR-proven SARS-CoV-2 infection we cannot detect specific antibodies. It has been suggested that less severe clinical manifestations might be associated with lower or absent antibody titers ¹³. However, there are also reports on asymptomatic subjects in whom neutralizing, specific antibodies against SARS-CoV-2 are being found ¹⁴. Another possibility is that the antibodies were produced, but that the antibody titers declined rapidly, especially as waning of specific antibodies after infection is a common feature observed in corona virus infections ^{15,16}. Also, recent data by Long *et al.* suggests that asymptomatic patients might develop weaker immunity against SARS-CoV-2 infection as indicated by an early decrease of IgG and neutralizing antibodies ¹⁷. Whether the low rate of seroconversion reflects early waning or whether these individuals in fact did not develop antibodies that could be detected with the applied tests, remains to be speculative.

Our post-outbreak seroprevalence cohort studies differs from similar studies ^{11,18} first by the "complete" cohort approach including children and infants instead of a representative sample and second by the extensive use of different antibody assays. An outbreak, similar in median age (58 years) and quarantine measures occurred on the Diamond Princess cruise ship ¹⁸. In this outbreak, of 3,711 exposed people, there were 619 confirmed SARS-CoV-2 infections corresponding to 17% of which 318 were symptomatic at the time of and 301 had symptoms before testing ¹⁸(*Table 1*). The infection fatality rate was estimated to be 1·3% (95% CI 0·38-3·6) and the case fatality rate twice higher (2·6%; 95% CI 0·89·6·7) reflecting the 50% of asymptomatic cases. Of note, case- and infection mortality rate dramatically increased in patients of 70 years and older. No data on antibody testing is available for this cohort. Rocklöv *et al.* modeled the effectiveness of infection control measures and suggested that the early intervention prevented 2,000 additional cases ¹⁹.

Most patients develop antibodies against SARS-CoV-2 within approximately one week after infection ¹³. Several investigators have reported 100% anti-SARS-CoV-2 IgG seropositivity in patients or in covalescent individuals ²⁰⁻²³. Using up to six different assays, we found that IgG antibodies were detectable in 39/52 subjects who had had suggestive symptoms of COVID-19 and in 20/38 participants with previously diagnosed SARS-CoV-2 infection. This confirms and extends earlier studies, in which IgG against different SARS-CoV-2 antigens were not

detectable in a fraction of patients who were examined at least 14 days after disease onset or convalescents ^{11,22,24}. Whereas in some reports the lowest reported rate in convalescent subjects was 77.9% (116/149 subjects) for anti-RBD-IgG and 69.8% (104/149) for anti-S-IgG in a study from New York ²⁴.

The significance of the finding that eight participants which reported a transient anosmia or loss of taste that had not previously been tested positive and were antibody negative, remains unclear. Also, the correlation between antibody titers and the level of protection currently is also unknown. Potent neutralizing antibodies have been detected in patients with high or low serum concentrations of antibodies measured by ELISA ²⁴ and the level of neutralizing antibodies has been reported to correlate with the number of SARS-CoV-2 specific T-cells ²⁵. The correlation between antibodies and protection against COVID-19 is further complicated by evidence suggesting antibody-induced disease enhancement in other coronavirus infections including SARS ²⁶. All available evidence indicates that antibody responses alone do not suffice to overcome SARS-CoV-2 infection. Data from SARS-CoV and MERS-CoV suggest that T-cell responses are required for protection and may last longer than antibody titers ²⁶⁻³⁰. Consequently, we are currently analyzing the neutralization capacity in cell culture systems and SARS-CoV-2 specific T-cell responses in our study participants.

Limitations

 Our study has several limitations: *i.*) our study was a population-based cohort study. We were able to recruit 71% of the community population. However, 29% of the population did not participate for unknown reasons which could introduce a bias in the assessment; *ii.*) the study was carried out six weeks after the end of the 14-day quarantine. This could have missed a number of participants that had a rapidly waning antibody response and *iii.*) there was no baseline of the antibody status before the quarantine as some participants might have been exposed earlier during the pandemic.

CONCLUSIONS

Our data questioned the relevance and reliability of IgG antibody testing to detect past SARS-CoV-2 infections six weeks after an outbreak. We conclude that assessing immunity for SARS-CoV-2 infection should not only rely on antibody tests but might also include the determination of neutralizing antibodies and potentially cellular immunity and requires long term follow up studies.

ABBREVIATIONS

CI	confidence interval
GEE	generalized estimation equations
MERS-CoV	Middle East respiratory syndrome-related coronavirus
OR	odds ratio
SARS-CoV	severe acute respiratory syndrome-related coronavirus

Funding: CoNAN was funded by the Sondervermögen "Corona" of the Thuringian Ministry for Economic Affairs, Science and Digital Society (TMWWDG).

Role of the Sponsor: The funding agency had no role in the design and conduct of the study; collection, management, analyses, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests: None declared.

Conflicts of Interest: SW received speaker fees from MSD and Infectopharm. SH received

- 1 speaker fees from Pfizer, MSD and Astra Zeneca. TK speaker fees from Roche MP has
- 2 participated in international advisory boards from Pfizer, Novartis, Basilea and Cubist and
- 3 received speaker fees from the same companies. CB has participated in advisory boards
- 4 from GSK and received speaking fees from Pfizer. All other authors do not report any conflict
- 5 of interest.

6 7 8

13

14

Acknowledgement

- 9 The project is carried out in cooperation with the district administration and the health
- 10 department of the Ilm-district and is funded by the Thuringian Ministry for Economic Affairs,
- 11 Science and Digital Society (TMWWDG). We thank Heike Kiesewetter, Anett Büschel and
- 12 Luzie Rösel for technical assistance.

REFERENCES

- 16 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
- 18 coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.
- 19 2. Whitworth J. COVID-19: a fast evolving pandemic. *Trans R Soc Trop Med Hyg* 2020;
- 20 **114**(4): 241-8.
- 21 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99
- 22 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet
- 23 2020; **395**(10223): 507-13.
- 24 4. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination
- 25 with other public health measures to control COVID-19: a rapid review. Cochrane Database
- 26 Syst Rev 2020; 4: CD013574.
- 27 5. Smith CE. Prospects for the control of infectious disease. *Proc R Soc Med* 1970;
- 28 **63**(11 Part 2): 1181-90.
- 29 6. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity
- 30 2020; **52**(5): 737-41.
- 7. Whitman JD, Hiatt J, Mowwery CT, et al. Test performance evaluation of SARS-CoV-
- 32 2 serological assay. *medRxiv preprint* 2020; **Version 2** (May 17).
- 33 8. Jaaskelainen AJ, Kuivanen S, Kekalainen E, et al. Performance of six SARS-CoV-2
- 34 immunoassays in comparison with microneutralisation. J Clin Virol 2020; 129: 104512.
- 35 9. WHO-2019. https://apps.who.int/iris/bitstream/handle/10665/331656/WHO-2019-
- 36 nCoV-Seroepidemiology-2020.1-eng.pdf?sequence=1&isAllowed=y. 2019.
- 37 10. Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic Seroconversion of
- 38 Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA 2020; 323(23): 2424-5.

- 1 11. Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2
- 2 infection in a German community with a super-spreading event. medRxiv preprint 2020;
- 3 Version 2(June 2).
- 4 12. Shields AM, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroconversion in
- 5 health care workers. *medRxiv preprint* 2020; **Version 1**(May 19).
- 6 13. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody
- 7 mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and
- 8 association of antibody responses with severity of disease. medRxiv Preprint 2020; Version 1
- 9 (Apr 17).
- 10 14. Kraehling V, Kern M, Halwe S, et al. Epidemiological study to detect active SARS-
- 11 CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt
- am Main metropolitan area. *medRxiv preprint* 2020; **Version 1**(May 25).
- 13 15. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune
- response to experimental coronavirus infection of man. Epidemiol Infect 1990; 105(2): 435-
- 15 46.
- 16 16. Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe
- acute respiratory syndrome. Emerg Infect Dis 2007; 13(10): 1562-4.
- 18 17. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of
- asymptomatic SARS-CoV-2 infections. *Nat Med* 2020.
- 20 18. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality
- 21 ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the
- 22 Diamond Princess cruise ship, February 2020. Euro Surveill 2020; 25(12).
- 23 19. Rocklov J, Sjodin H, Wilder-Smith A. COVID-19 outbreak on the Diamond Princess
- cruise ship: estimating the epidemic potential and effectiveness of public health
- countermeasures. J Travel Med 2020; 27(3).
- 26 20. Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses
- in COVID-19 patients. Emerg Microbes Infect 2020; 9(1): 940-8.
- 28 21. Jiang HW, Li Y, Zhang HN, et al. Global profiling of SARS-CoV-2 specific IgG/ IgM
- 29 responses of convalescents using a proteome microarray. Nat Commun 2020; 11(1): 3581.
- 30 22. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior
- 31 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-
- 32 2: an observational cohort study. Lancet Infect Dis 2020; **20**(5): 565-74.
- 33 23. Xiang F, Wang X, He X, et al. Antibody Detection and Dynamic Characteristics in
- Patients with COVID-19. Clin Infect Dis 2020; ciaa461.

- 1 24. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to
- 2 SARS-CoV-2 in convalescent individuals. *Nature* 2020. Jun 18.
- 3 25. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular
- 4 Immunity in COVID-19 Convalescent Individuals. *Immunity* 2020; **52**(6): 971-7 e3.
- 5 26. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the
- 6 Science. *Immunity* 2020; **52**(6): 910-41.
- 7 27. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: Implications for vaccine
- 8 development against MERS-CoV. Antiviral Res 2017; 137: 82-92.
- 9 28. Chen J, Subbarao K. The Immunobiology of SARS*. Annu Rev Immunol 2007; 25:
- 10 443-72.
- 11 29. Zhao J, Zhao J, Mangalam AK, et al. Airway Memory CD4(+) T Cells Mediate
- 12 Protective Immunity against Emerging Respiratory Coronaviruses. *Immunity* 2016; **44**(6):
- 13 1379-91.

- 14 30. Tang F, Quan Y, Xin ZT, et al. Lack of peripheral memory B cell responses in
- 15 recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J
- 16 *Immunol* 2011; **186**(12): 7264-8.

FIGURES AND TABLES

<u>Figure 1:</u> Flow chart of the CoNAN study. * PCR from pharyngeal washes obtained during the CoNAN study in May 2020.

- <u>Figure 2:</u> Upset Plot showing the comparison of test performance between the six serological IgG tests used to evaluate the antibody response in the CoNAN study.
- 9 Abbreviations: DS..SARS-CoV-2 S1/S2 IgG CLIA kit (DiaSorin, Saluggia, Italy); ED..EDI
- 10 Novel Coronavirus SARS-CoV-2 IgG ELISA kit (Epitope Diagnostics Inc., San Diego, USA);
- 11 EU..SARS-COV-2 IgG ELISA kit (Euroimmun, Lübeck, Germany); SN.2019-nCoV IgG kit
- 12 (Snibe Co., Ltd., Shenzhen, China).
- Figure 3: Cross tables of A) antibody status vs. SARS-CoV-2 PCR-results (initial mass testing); B) symptoms vs. SARS-CoV-2 PCR-results (initial mass testing); C) symptoms vs. antibody status. The estimated odds ratios for antibody status (A), any symptoms (B, C) are derived from a logistic GEE model adjusted for sex and age (linear). Note that A) and B) are limited to those 610 participants with an available initial mass-testing PCR-result. Abbreviations: Cl..confidence interval, OR..odds ratio.
 - <u>Figure 4:</u> Associations for reported clinical symptoms and positive antibody status for A) all participants, B) previously SARS-CoV-2 PCR-positive and C) previously SARS-CoV-2 PCR-negative. Odds ratio and corresponding 95% confidence interval are derived from the logistic GEE model adjusted for household clustering and sex and age (linear); the plots display the complete cases.

<u>Table 1:</u> Characteristics of the analyzed (*i.e.* with serum samples) 562 adult participants stratified by serostatus and the analyzed (*i.e.* with serum samples) 58 participating adolescents and children. Abbreviations: no..number; SD..standard deviation

Characteristic	Adults			
	Sero-negative Sero-positive Ov (N=511) (N=51) (N=			adolescents Overall (N=58)*
Size of household clusters	, ,		,	. ,
1 person	84 (16.4%)	6 (11.8%)	90 (16.0%)	0 (0%)
2 persons	216 (42.3%)	31 (60.8%)	247 (44.0%)	0 (0%)
3 persons	108 (21.1%)	5 (9.8%)	113 (20.1%)	18 (31.0%)
4 persons	57 (11.2%)	7 (13.7%)	64 (11.4%)	32 (55.2%)
5+ persons	44 (8.6%)	1 (2.0%)	45 (8.0%)	5 (8.6%)
Missing	2 (0.4%)	1 (2.0%)	3 (0.5%)	3 (5.2%)
Sex - no.(%)	,	,	,	,
Male	238 (46.6%)	28 (54.9%)	266 (47.3%)	35 (60.3%)
Female	273 (53.4%)	23 (45.1%)	296 (52.7%)	22 (37.9%)
Missing	,	,	,	1 (1.7%)
Age (years)				, ,
Mean (SD)	57.9 (16.8)	60.3 (13.2)	58.1 (16.5)	9.62 (4.38)
Median [Min, Max]	60 [18, 97]	62 [24, 83]	60 [18, 97]	10 [1, 17]
PCR during quarantine (reported)		- [,]		- [,]
- no.(%)				
negative	490 (95.9%)	31 (60.8%)	521 (92.7%)	51 (87.9%)
positive	16 (3.1%)	20 (39.2%)	36 (6.4%)	2 (3.4%)
not known	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing	5 (1.0%)	0 (0%)	5 (0.9%)	5 (8.6%)
Chron. lung disease - no.(%)	, ,	, ,	, ,	, ,
Yes	44 (8.6%)	3 (5.9%)	47 (8.4%)	2 (3.4%)
No	465 (91.0%)	48 (94.1%)	513 (91.3%)	52 (89.7%)
not known	1 (0.2%)	0 (0%)	1 (0.2%)	1 (1.7%)
Missing	1 (0.2%)	0 (0%)	1 (0.2%)	3 (5.2%)
Cardiovascular disease - no.(%)	,	` ,	,	, ,
Yes	252 (49.3%)	24 (47.1%)	276 (49.1%)	0 (0%)
No	248 (48.5%)	26 (51.0%)	274 (48.8%)	58 (100%)
not known	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing	11 (2.2%)	1 (2.0%)	12 (2.1%)	(/
Diabetes - no.(%)	(,	(,	(
Yes	89 (17.4%)	5 (9.8%)	94 (16.7%)	0 (0%)
No	420 (82.2%)	45 (88.2%)	465 (82.7%)	55 (94.8%)
not known	2 (0.4%)	1 (2.0%)	3 (0.5%)	0 (0%)
Missing	_ (0/0)	. (=.070)	0 (0.070)	3 (5.2%)
Cancer - no.(%)				0 (0.270)
Yes	34 (6.7%)	1 (2.0%)	35 (6.2%)	0 (0%)
No	474 (92.8%)	50 (98.0%)	524 (93.2%)	55 (94.8%)
not known	3 (0.6%)	0 (0%)	3 (0.5%)	0 (0%)
Missing	3 (3.070)	J (370)	3 (3.070)	3 (5.2%)
Autoimmune diseases / immune deficiency - no.(%)				3 (0.270)
Yes	22 (4.3%)	3 (5.9%)	25 (4.4%)	0 (0%)
No	485 (94.9%)	47 (92.2%)	532 (94.7%)	55 (94.8%)
not known	4 (0.8%)	1 (2.0%)	5 (0.9%)	0 (0%)
Missing	. (3.070)	. (=.070)	0 (0.070)	3 (5.2%)

Smoker - no.(%)				
No	335 (65.6%)	42 (82.4%)	377 (67.1%)	55 (94.8%)
Current smoker	122 (23.9%)	5 (9.8%)	127 (22.6%)	0 (0%)
Former smoker	52 (10.2%)	4 (7.8%)	56 (10.0%)	0 (0%)
Missing	2 (0.4%)	0 (0%)	2 (0.4%)	3 (5.2%)

^{*}note that only one individual was characterized as "Sero-positive"

<u>Table 2:</u> Characteristics of the analyzed (*i.e.* with serum samples) 562 adult participants stratified by serostatus and the analyzed (*i.e.* with serum samples) 58 participating adolescents and children. Abbreviations: no..number; SD..standard deviation

Sero-negative (N=511)	(N=562) (%) 137 (24.4%) (%) 422 (75.1%) (%) 3 (0.5%) (%) 27 (4.8%) (%) 535 (95.2%) (%) 17 (3.0%) (%) 545 (97.0%) (%) 34 (6.0%)	Overall (N=58)* 14 (24.1%) 41 (70.7%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%) 51 (87.9%)
last 2 months? Yes	422 (75.1%) 3 (0.5%) 422 (75.1%) 3 (0.5%) 46) 27 (4.8%) 535 (95.2%) 47 (3.0%) 545 (97.0%) 48 34 (6.0%)	41 (70.7%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
Yes 105 (20.5%) 32 (62.7°) No 404 (79.1%) 18 (35.3°) Missing 2 (0.4%) 1 (2.0%) Loss of taste 7 (1.4%) 20 (39.2°) No 504 (98.6%) 31 (60.8°) Missing 8 40 (78.4°) Loss of smell 6 (1.2%) 11 (21.6°) Yes 6 (1.2%) 11 (21.6°) No 505 (98.8%) 40 (78.4°) Missing 23 (4.5%) 11 (21.6°) No 488 (95.5%) 40 (78.4°) Missing 511 (100%) 51 (100%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough 74 74 (13.9%) 24 (47.1°) No 440 (86.1%) 27 (52.9°) No 442 (86.5%) 43 (84.3°) No <td>422 (75.1%) 3 (0.5%) 422 (75.1%) 3 (0.5%) 46) 27 (4.8%) 535 (95.2%) 47 (3.0%) 545 (97.0%) 48 34 (6.0%)</td> <td>41 (70.7%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)</td>	422 (75.1%) 3 (0.5%) 422 (75.1%) 3 (0.5%) 46) 27 (4.8%) 535 (95.2%) 47 (3.0%) 545 (97.0%) 48 34 (6.0%)	41 (70.7%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
No 404 (79.1%) 18 (35.3° Missing 2 (0.4%) 1 (2.0%) Loss of taste Yes 7 (1.4%) 20 (39.2° No 504 (98.6%) 31 (60.8° Missing Loss of smell Yes 6 (1.2%) 11 (21.6° No 505 (98.8%) 40 (78.4° Missing Fever Yes 23 (4.5%) 11 (21.6° No 488 (95.5%) 40 (78.4° Missing Headache Yes 0 (0%) 0 (0%) No 0	422 (75.1%) 3 (0.5%) 422 (75.1%) 3 (0.5%) 46) 27 (4.8%) 535 (95.2%) 47 (3.0%) 545 (97.0%) 48 34 (6.0%)	41 (70.7%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
Missing 2 (0.4%) 1 (2.0%) Loss of taste Yes 7 (1.4%) 20 (39.2° No 504 (98.6%) 31 (60.8° Missing Loss of smell Yes 6 (1.2%) 11 (21.6° No 505 (98.8%) 40 (78.4° Missing Fever Yes 23 (4.5%) 11 (21.6° No 488 (95.5%) 40 (78.4° Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough Yes 71 (13.9%) 24 (47.1° No 440 (86.1%) 27 (52.9° Missing Nose congestion Yes 67 (13.1%) 8 (15.7° No 442 (86.5%) 43 (84.3° Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6° No 475 (93.0%) 40 (78.4°	3 (0.5%) 27 (4.8%) 535 (95.2%) 3 (0.5%) 40 545 (97.0%) 34 (6.0%)	3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
Loss of taste Yes 7 (1.4%) 20 (39.2° No 504 (98.6%) 31 (60.8° Missing Loss of smell Yes 6 (1.2%) 11 (21.6° No 505 (98.8%) 40 (78.4° Missing Fever Yes 23 (4.5%) 11 (21.6° No 488 (95.5%) 40 (78.4° Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100° Cough Yes 71 (13.9%) 24 (47.1° No 440 (86.1%) 27 (52.9° Missing Nose congestion Yes 67 (13.1%) 8 (15.7° No 442 (86.5%) 43 (84.3° Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6° No 475 (93.0%) 40 (78.4°	27 (4.8%) 535 (95.2%) 60) 17 (3.0%) 545 (97.0%) 60) 34 (6.0%)	0 (0%) 55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
Yes 7 (1.4%) 20 (39.2°) No 504 (98.6%) 31 (60.8°) Missing 31 (60.8°) Loss of smell 40 (78.4°) Yes 6 (1.2%) 11 (21.6°) No 505 (98.8%) 40 (78.4°) Missing 23 (4.5%) 11 (21.6°) No 488 (95.5%) 40 (78.4°) Missing 511 (100%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough 71 (13.9%) 24 (47.1°) No 440 (86.1%) 27 (52.9°) Missing 70 (13.1%) 8 (15.7°) No 442 (86.5%) 43 (84.3°) Missing 2 (0.4%) 0 (0%) Sore throat 7 7 7 7 7 7 No 475 (93.0%) 40 (78.4°) 40 (78.4°) 40 (78.4°) 40 (78.4°)	535 (95.2%) 17 (3.0%) 545 (97.0%) 34 (6.0%)	55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
No 504 (98.6%) 31 (60.8%) Missing Loss of smell Yes 6 (1.2%) 11 (21.6%) No 505 (98.8%) 40 (78.4%) Missing Fever Yes 23 (4.5%) 11 (21.6%) No 488 (95.5%) 40 (78.4%) Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough Yes 71 (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing Nose congestion Yes 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)	535 (95.2%) 17 (3.0%) 545 (97.0%) 34 (6.0%)	55 (94.8%) 3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
Missing Loss of smell Yes 6 (1.2%) 11 (21.6° No 505 (98.8%) 40 (78.4° Missing Fever Yes 23 (4.5%) 11 (21.6° No 488 (95.5%) 40 (78.4° Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) No 0 (0%) 511 (100%) Cough Yes 71 (13.9%) 24 (47.1° No 440 (86.1%) 27 (52.9° Missing Nose congestion Yes 67 (13.1%) 8 (15.7% No 442 (86.5%) 43 (84.3° Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6° No 475 (93.0%) 40 (78.4°	%) 17 (3.0%) %) 545 (97.0%) %) 34 (6.0%)	3 (5.2%) 0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
Loss of smell Yes 6 (1.2%) 11 (21.60 No 505 (98.8%) 40 (78.40 Missing Fever Yes 23 (4.5%) 11 (21.60 No 488 (95.5%) 40 (78.40 Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough Yes 71 (13.9%) 24 (47.10 No 440 (86.1%) 27 (52.90 Missing Nose congestion Yes 67 (13.1%) 8 (15.7% No 442 (86.5%) 43 (84.30 Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.60 No 475 (93.0%) 40 (78.40)	545 (97.0%) 34 (6.0%)	0 (0%) 55 (94.8%) 3 (5.2%) 4 (6.9%)
Yes 6 (1.2%) 11 (21.6° No 505 (98.8%) 40 (78.4° Missing Fever Yes 23 (4.5%) 11 (21.6° No 488 (95.5%) 40 (78.4° Missing 11 (21.6° 40 (78.4° Missing 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough 71 (13.9%) 24 (47.1° No 440 (86.1%) 27 (52.9° Missing 8 (15.7° No 442 (86.5%) 43 (84.3° Missing 2 (0.4%) 0 (0%) Sore throat 36 (7.0%) 11 (21.6° No 475 (93.0%) 40 (78.4°	545 (97.0%) 34 (6.0%)	55 (94.8%) 3 (5.2%) 4 (6.9%)
No 505 (98.8%) 40 (78.4%) Missing Fever Yes 23 (4.5%) 11 (21.6% No 488 (95.5%) 40 (78.4%) Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 51 (100%) Missing 511 (100%) 51 (100%) Cough Yes 71 (13.9%) 24 (47.1% No 440 (86.1%) 27 (52.9%) Missing Nose congestion Yes 67 (13.1%) 8 (15.7% No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)	545 (97.0%) 34 (6.0%)	55 (94.8%) 3 (5.2%) 4 (6.9%)
Missing Fever Yes 23 (4.5%) 11 (21.6° No 488 (95.5%) 40 (78.4° Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough Yes 71 (13.9%) 24 (47.1° No 440 (86.1%) 27 (52.9° Missing Nose congestion Yes 67 (13.1%) 8 (15.7° No 442 (86.5%) 43 (84.3° Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6° No 475 (93.0%) 40 (78.4°)	%) 34 (6.0%)	3 (5.2%) 4 (6.9%)
Fever Yes 23 (4.5%) 11 (21.6°) No 488 (95.5%) 40 (78.4°) Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough 71 (13.9%) 24 (47.1°) No 440 (86.1%) 27 (52.9°) Missing No 442 (86.5%) 43 (84.3°) No 442 (86.5%) 43 (84.3°) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6°) No 475 (93.0%) 40 (78.4°)		4 (6.9%)
Yes 23 (4.5%) 11 (21.60 No 488 (95.5%) 40 (78.40 Missing Headache Yes 0 (0%) 0 (0%) 0 (0%) No 0 (0%) 51 (100%) 51 (100%) Cough Yes 71 (13.9%) 24 (47.10 No 440 (86.1%) 27 (52.90 Missing Nose congestion Yes 67 (13.1%) 8 (15.70 No 442 (86.5%) 43 (84.30 Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.60 No 475 (93.0%) 40 (78.40 No 475 (93.0%) 40 (78.40 No 488 (95.5%) 43 (84.30 No 475 (93.0%) 40 (78.40 No 475 (93.0%) 40 (78.40 No 488 (95.5%) 41 (21.60 No 475 (93.0%) 40 (78.40 No 488 (95.5%) 43 (84.30 No 475 (93.0%) 40 (78.40 No 488 (95.5%) 43 (84.30 No 475 (93.0%) 40 (78.40 No 475 (93.		
No 488 (95.5%) 40 (78.4%) Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 51 (100%) Missing 511 (100%) 51 (100%) Cough 71 (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)		
Missing Headache Yes 0 (0%) 0 (0%) No 0 (0%) 51 (100%) Missing 511 (100%) 51 (100%) Cough 71 (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing Nose congestion Yes 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)	%) 528 (94.0%)	31 (07.870)
Headache Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough To (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing Nose congestion Yes 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)	76) 320 (94.076)	3 (5.2%)
Yes 0 (0%) 0 (0%) No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough To (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing Nose congestion Yes 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)		3 (3.276)
No 0 (0%) 0 (0%) Missing 511 (100%) 51 (100%) Cough 71 (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)	0 (00/)	0 (00/)
Missing 511 (100%) 51 (100%) Cough 71 (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)	` ,	0 (0%) 0 (0%)
Cough Yes 71 (13.9%) 24 (47.1%) No 440 (86.1%) 27 (52.9%) Missing Nose congestion Yes 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)		
Yes 71 (13.9%) 24 (47.1° No 440 (86.1%) 27 (52.9° Missing 8 (15.7° No 67 (13.1%) 8 (15.7° No 442 (86.5%) 43 (84.3° Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6° No 475 (93.0%) 40 (78.4°)	%) 562 (100%)	58 (100%)
No 440 (86.1%) 27 (52.9° Missing Nose congestion 7 Yes 67 (13.1%) 8 (15.7° Missing No 442 (86.5%) 43 (84.3° Missing Sore throat 2 (0.4%) 0 (0%) Sore throat 36 (7.0%) 11 (21.6° Missing No 475 (93.0%) 40 (78.4° Missing)/) OF (4C 00/)	0 (40 00/)
Missing Nose congestion Yes 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)		8 (13.8%)
Nose congestion 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)	%) 467 (83.1%)	46 (79.3%)
Yes 67 (13.1%) 8 (15.7%) No 442 (86.5%) 43 (84.3%) Missing 2 (0.4%) 0 (0%) Sore throat Yes 36 (7.0%) 11 (21.6%) No 475 (93.0%) 40 (78.4%)		4 (6.9%)
No 442 (86.5%) 43 (84.3°) Missing 2 (0.4%) 0 (0%) Sore throat 7es 36 (7.0%) 11 (21.6°) No 475 (93.0%) 40 (78.4°)	() 75 (40.00()	40 (07 00()
Missing 2 (0.4%) 0 (0%) Sore throat 36 (7.0%) 11 (21.6°) No 475 (93.0%) 40 (78.4°)		16 (27.6%)
Sore throat Yes 36 (7.0%) 11 (21.6°) No 475 (93.0%) 40 (78.4°)		38 (65.5%)
Yes 36 (7.0%) 11 (21.6° No 475 (93.0%) 40 (78.4°	2 (0.4%)	4 (6.9%)
No 475 (93.0%) 40 (78.4°		
		10 (17.2%)
Missing	%) 515 (91.6%)	45 (77.6%)
		3 (5.2%)
Shortness of breath		
Yes 10 (2.0%) 9 (17.6%)	, , ,	0 (0%)
No 501 (98.0%) 42 (82.4°	%) 543 (96.6%)	55 (94.8%)
Missing		3 (5.2%)
Other respiratory symptoms		
Yes 9 (1.8%) 5 (9.8%)	1 1 10 =0/1	0 (0%)
No 502 (98.2%) 46 (90.2°	,	55 (94.8%)
Missing	,	3 (5.2%)
Fatigue	, , ,	
Yes 46 (9.0%) 22 (43.1°	, , ,	3 (5.2%)
No 465 (91.0%) 29 (56.9°	548 (97.5%)	
Missing	548 (97.5%) 68 (12.1%)	52 (89.7%)

Sweats and chills				
Yes	26 (5.1%)	14 (27.5%)	40 (7.1%)	5 (8.6%)
No	485 (94.9%)	37 (72.5%)	522 (92.9%)	50 (86.2%)
Missing				3 (5.2%)
Muscle and joint ache				
Yes	35 (6.8%)	16 (31.4%)	51 (9.1%)	3 (5.2%)
No	476 (93.2%)	35 (68.6%)	511 (90.9%)	52 (89.7%)
Missing				3 (5.2%)
Nausea, vomiting, stomach pain				
Yes	24 (4.7%)	8 (15.7%)	32 (5.7%)	6 (10.3%)
No	487 (95.3%)	43 (84.3%)	530 (94.3%)	49 (84.5%)
Missing				3 (5.2%)

^{*}note that only one individual was characterized as "Sero-positive"

1

medRxiv preprint doi: https://doi.org/10.1101/2020.07.15.20154112; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license. Inhabitants of "Neustadt am Rennsteig" (A9 positive from 865)

No participation (n=257)

Study participants (n=626)

SARS-CoV-2 PCR (0 positive from 617)*

No plasma samples (n=6)

Analyzed participants (n=620)

Participants with 6 serological test (n=600)

Adults (n=562)

Children/Adolescents (n=58)

Sero-negative

(n=57)

Sero-positive

(n=1)


Sero-negative


(n=511)

Sero-positive


(n=51)

medRxiv preprint doi: https://doi.org/10.1101/2020.07.15.20154112; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made a license a cC-BY-ND 4.0 International license.






medRxiv preprint do: https://doi.org/10.1101/2020.07.15.20154112; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.



B

PCR-positive



С

PCR-negative

